1
|
Wan Q, Xie Y, Zhou Y, Shen X. Research progress on the relationship between sex hormone-binding globulin and male reproductive system diseases. Andrologia 2020; 53:e13893. [PMID: 33112478 DOI: 10.1111/and.13893] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Revised: 09/28/2020] [Accepted: 10/06/2020] [Indexed: 12/14/2022] Open
Abstract
Sex hormone-binding globulin, also known as testosterone-estradiol-binding globulin, is a multifunctional protein synthesised by hepatocytes. Sex hormone-binding globulin specifically binds and transports sex hormones to regulate plasma bioactive sex hormone levels and affects their bioavailability. As male sex hormone expression is dominated by testosterone, the binding of sex hormone-binding globulin with testosterone leads to the reduction in bioavailable testosterone, which cannot fulfil its physiological roles, thereby resulting in male infertility, erectile and gonadal dysfunction, prostate cancer and other male reproductive system diseases. Sex hormone-binding globulin may be involved in the pathogenesis of male reproductive system diseases, seriously affecting the quality of life of men. In this article, we review the association between sex hormone-binding globulin and male reproductive system diseases.
Collapse
Affiliation(s)
- Qiyou Wan
- School of Public Health, Zunyi Medical University, Zunyi, Guizhou, China
| | - Yan Xie
- School of Public Health, Zunyi Medical University, Zunyi, Guizhou, China
| | - Yuanzhong Zhou
- School of Public Health, Zunyi Medical University, Zunyi, Guizhou, China
| | - Xubo Shen
- School of Public Health, Zunyi Medical University, Zunyi, Guizhou, China
| |
Collapse
|
2
|
Dell’Atti L, Galosi AB. The role of the serum testosterone levels as a predictor of prostate cancer in patients with atypical small acinar proliferation at the first prostate biopsy. Asian J Androl 2018; 20:15-18. [PMID: 28695864 PMCID: PMC5753548 DOI: 10.4103/aja.aja_17_17] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2016] [Accepted: 04/25/2017] [Indexed: 11/04/2022] Open
Abstract
The current literature does not support the usefulness of clinical markers on predicting which patients with atypical small acinar proliferation (ASAP) are more likely to progress to prostate cancer (PCa). Androgens have long been considered to be the potential risk factors for PCa. However, the role of testosterone is controversial. The present study aims to analyze the relationship between serum testosterone (TS) levels and the diagnosis of PCa after a first prostate biopsy in patients affected by ASAP. This retrospective study included 143 patients diagnosed with ASAP in an initial transrectal ultrasound-guided prostate biopsy for suspicious PCa according to the European Association of Urology guidelines. Their TS levels, age, PSA, prostate volume, digital rectal examination, and prostate biopsy Gleason score (GS) were collected retrospectively for statistical analysis. All patients included in the study had a second biopsy and were suitable for further analysis. Re-biopsy was carried out 3-6 months after the first diagnosis of ASAP. Low and normal TS groups were composed of 29 (20.3%) and 114 (79.7%) patients, respectively. The diagnosis of the second biopsy was ASAP in 25.2% and PCa in 36.4% of patients. The comparison between patients with PCa and those with negative or an ASAP result in the second biopsy reported that men with cancer had significantly higher levels of TS (P < 0.001). However, there was no statistically significant association between GS postbiopsy and TS (P = 0.324). Our experience demonstrated that eugonadal patients may be a clinical risk factor for the diagnosis of PCa on re-biopsy after ASAP diagnosis than hypogonadal.
Collapse
Affiliation(s)
- Lucio Dell’Atti
- Department of Urology, University Hospital St. Anna, Ferrara 44124, Italy
| | - Andrea B Galosi
- Department of Urology, Polytechnic University of Marche, Ancona 60126, Italy
| |
Collapse
|
3
|
Fiamegos A, Varkarakis J, Kontraros M, Karagiannis A, Chrisofos M, Barbalias D, Deliveliotis C. Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result. Int Braz J Urol 2017; 42:925-931. [PMID: 27532110 PMCID: PMC5066888 DOI: 10.1590/s1677-5538.ibju.2015.0167] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2015] [Accepted: 11/29/2015] [Indexed: 11/22/2022] Open
Abstract
INTRODUCTION Data from animal, clinical and prevention studies support the role of androgens in prostate cancer growth, proliferation and progression. Results of serum based epidemiologic studies in humans, however, have been inconclusive. The present study aims to define whether serum testosterone can be used as a predictor of a posi¬tive second biopsy in males considered for re-biopsy. MATERIAL AND METHODS The study included 320 men who underwent a prostatic biopsy in our department from October 2011 until June 2012. Total testosterone, free testos¬terone, bioavailable testosterone and prostate pathology were evaluated in all cases. Patients undergoing a second biopsy were identified and biopsy results were statistically analyzed. RESULTS Forty men (12.5%) were assessed with a second biopsy. The diagnosis of the second biopsy was High Grade Intraepithelial Neoplasia in 14 patients (35%) and Prostate Cancer in 12 patients (30%). The comparison of prostatic volume, total testosterone, sex hormone binding globulin, free testosterone, bioavailable testosterone and albumin showed that patients with cancer of the prostate had significantly greater levels of free testosterone (p=0.043) and bioavailable T (p=0.049). CONCLUSION In our study, higher free testosterone and bioavailable testosterone levels were associated with a cancer diagnosis at re-biopsy. Our results indicate a possible role for free and bioavailable testosterone in predicting the presence of prostate cancer in patients considered for re-biopsy.
Collapse
Affiliation(s)
- Alexandros Fiamegos
- 2nd Department of Urology, University of Athens, Sismanoglio General Hospital, Athens, Greece
| | - John Varkarakis
- 2nd Department of Urology, University of Athens, Sismanoglio General Hospital, Athens, Greece
| | - Michael Kontraros
- 2nd Department of Urology, University of Athens, Sismanoglio General Hospital, Athens, Greece
| | - Andreas Karagiannis
- 2nd Department of Urology, University of Athens, Sismanoglio General Hospital, Athens, Greece
| | - Michael Chrisofos
- 2nd Department of Urology, University of Athens, Sismanoglio General Hospital, Athens, Greece
| | - Dimitrios Barbalias
- 2nd Department of Urology, University of Athens, Sismanoglio General Hospital, Athens, Greece
| | | |
Collapse
|
4
|
Fuentes-Pastor J, Pellejero P, Ortiz I, Ramírez-Backhaus M, de Gracia A, Marrugo C, Gomez-Ferrer A, Calatrava A, Rubio-Briones J, Rodriguez-Torreblanca C, Solsona-Narbón E. Association between late-onset hypogonadism syndrome plus metabolic syndrome and prostate cancer and its aggressiveness. Actas Urol Esp 2016; 40:440-5. [PMID: 27091367 DOI: 10.1016/j.acuro.2016.02.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2015] [Revised: 02/07/2016] [Accepted: 02/08/2016] [Indexed: 01/05/2023]
Abstract
OBJECTIVE To assess the relationship between prostate cancer (PC) and the presence of metabolic syndrome and late-onset hypogonadism (LOH) syndrome. MATERIAL AND METHOD A retrospective study was conducted on 686 patients who underwent prostate biopsy. We analysed the demographic variables, clinical data and biopsy results. To diagnose metabolic syndrome, we employed the criteria of the American Heart Association. For the diagnosis of LOH syndrome, we employed the Androgen Deficiency in the Aging Male questionnaire and testosterone levels (TT). We evaluated the relationship between free testosterone (FT) and bioavailable testosterone (BT) on one hand and PC and its aggressiveness on the other, as well as the usefulness of the TT to prostate specific antigen (TT/PSA) ratio in the PC diagnosis. RESULTS The patient's median age was 65 years. Metabolic syndrome is not associated with PC (39.4% vs. 35%; P=.1) but is associated with a PC Gleason score >7 (50.4% vs. 29.44%; P=.002). LOH, low FT and low BT are associated with an increased presence of PC (51% vs. 35%, P=.02; 44.86% vs. 33.33%, P=.03; and 46.46% vs. 33.08%, P=.01, respectively) and with an increased probability of a PC Gleason score >7 (61.54% vs. 37.5%, P=.02; 54.17% vs. 34.12%, P=.02; 54.35% vs. 34.48%, P=.02, respectively). Additionally, the median TT/PSA ratio was significantly lower in patients with positive biopsies (P=.022). CONCLUSIONS Metabolic syndrome was not associated with the probability of having PC but was associated with a PC Gleason score >7. Moreover, LOH syndrome had a higher percentage of PC and a greater presence of PC Gleason scores >7, as did low levels of FT and low levels of BT.
Collapse
Affiliation(s)
- J Fuentes-Pastor
- Servicio de Urología, Hospital Universitario de Marqués de Valdecilla (HUMV), Santander, España
| | - P Pellejero
- Servicio de Urología, Hospital Universitario Central de Asturias (HUCA), Oviedo, España
| | - I Ortiz
- Departamento de Matemática Aplicada, Universidad de Almería, Almería, España
| | - M Ramírez-Backhaus
- Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España.
| | - A de Gracia
- Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España
| | - C Marrugo
- Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España
| | - A Gomez-Ferrer
- Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España
| | - A Calatrava
- Servicio de Anatomía Patológica, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España
| | - J Rubio-Briones
- Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España
| | | | - E Solsona-Narbón
- Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España
| |
Collapse
|
5
|
Regis L, Planas J, Celma A, de Torres I, Ferrer R, Morote J. Behavior of total and free serum testosterone as a predictor for the risk of prostate cancer and its aggressiveness. Actas Urol Esp 2015; 39:573-81. [PMID: 25944770 DOI: 10.1016/j.acuro.2015.03.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2015] [Revised: 03/12/2015] [Accepted: 03/13/2015] [Indexed: 10/23/2022]
Abstract
CONTEXT Serum testosterone is mostly bound to the sex hormone-binding globulin and albumin. A small metabolically active part is present in the form of free testosterone (FT). The relationship between serum total testosterone (TT) levels and prostate carcinogenesis is debated. Our hypothesis is that the serum FT concentration is more closely associated with the risk of prostate cancer (PC) and its aggressiveness than TT. OBJECTIVE To analyze the scientific evidence that relates serum TT and/or FT levels with the diagnosis of PC and its aggressiveness. ACQUISITION OF EVIDENCE A systematic review was conducted in PubMed up to January 2015 using the following mesh terms: prostate cancer, sex hormone, androgen, testosterone and free testosterone. SYNTHESIS OF THE EVIDENCE We found 460 publications, 124 of which were reviewed to analyze the evidence. The relationship between serum TT levels and the diagnosis of PC and its aggressiveness is highly heterogeneous. The variability in the design of the studies, the quantification methods and other variables could explain this heterogeneity. In a number of studies that evaluated the estimated or measured FT, the evidence remains equally conflicting. CONCLUSIONS Based on the current evidence, we cannot recommend the measurement of serum TT and/or TL levels for the diagnosis of PC or for assessing its aggressiveness.
Collapse
|
6
|
Eisenberg ML, Li S, Betts P, Herder D, Lamb DJ, Lipshultz LI. Testosterone therapy and cancer risk. BJU Int 2014; 115:317-21. [DOI: 10.1111/bju.12756] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Michael L. Eisenberg
- Department of Urology; Stanford University School of Medicine; Stanford CA USA
- Department of Obstetrics/Gynecology; Stanford University School of Medicine; Stanford CA USA
| | - Shufeng Li
- Department of Urology; Stanford University School of Medicine; Stanford CA USA
- Department of Dermatology; Stanford University School of Medicine; Stanford CA USA
| | - Paul Betts
- Cancer Epidemiology and Surveillance Branch; Texas Cancer Registry; Texas Department of State Health Services; Austin TX USA
| | - Danielle Herder
- Scott Department of Urology; Baylor College of Medicine; Houston TX USA
| | - Dolores J. Lamb
- Scott Department of Urology; Baylor College of Medicine; Houston TX USA
| | | |
Collapse
|
7
|
Friedersdorff F, Manus P, Miller K, Lein M, Jung K, Stephan C. Serum testosterone improves the accuracy of Prostate Health Index for the detection of prostate cancer. Clin Biochem 2014; 47:916-20. [DOI: 10.1016/j.clinbiochem.2014.02.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2013] [Revised: 01/31/2014] [Accepted: 02/03/2014] [Indexed: 10/25/2022]
|
8
|
García-Cruz E, Castañeda-Argáiz R, Carrión A, Alcover J, Sallent A, Leibar-Tamayo A, Romero-Otero J, Alcaraz A. Preoperative hormonal pattern in patients undergoing radical prostatectomy due to prostate cancer. Actas Urol Esp 2013; 37:280-5. [PMID: 23246101 DOI: 10.1016/j.acuro.2012.08.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2012] [Revised: 08/02/2012] [Accepted: 08/07/2012] [Indexed: 11/30/2022]
Abstract
OBJECTIVE There is controversial evidence regarding preoperative testosterone (T) levels related to poor prognosis factors after radical prostatectomy (RP). The aim of this manuscript is to determine the relationship between preoperative T levels and final pathologic report together to biochemical recurrence after RP. MATERIALS AND METHODS We prospectively analysed 143 patients submitted to RP from February 2008 to June 2010 in our centre. Pretreatment T and sex hormone-binding globulin levels were determined as part of our clinical protocol. Free calculated (fT) and bioavailable (bioT) T were calculated using Vermeulen's formula. Low T levels were defined as 346 ng/dL or less. A comparative analysis with variables pTNM, positive margins, tumour burden, Gleason score, multifocality and biochemical recurrence (using both PSA>0.4 ng/dL and PSA>0.2 ng/dL as cut-off values) was performed, according to preoperative levels of T. RESULTS Variables Gleason score, rate and number of positive margins, tumour burden, tumour multifocality, time to biochemical recurrence and pathological stage were not related to preoperative hormonal levels. Preoperative T<346 ng/dL was not found to be related to PSA recurrence (PSA>0,4 ng/dL log-rank, P=.512), although a trend was observed when PSA>0,2 ng/dL (log-rank, P=.097). CONCLUSION Preoperative T levels were not related to final pathological report or to biochemical recurrence.
Collapse
Affiliation(s)
- E García-Cruz
- Departamento de Urología, Hospital Clínic, Barcelona, España.
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Lasselin J, Drouin SJ, Champy CM, Léon P, Casenave J, Cussenot O, Bitker MO, Rouprêt M. [Influence of plasmatic testosterone during natural history of prostate cancer: a review]. Prog Urol 2013; 23:438-43. [PMID: 23721702 DOI: 10.1016/j.purol.2013.01.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2012] [Revised: 12/10/2012] [Accepted: 01/13/2013] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Prostate cancer (PCa) is the most common disease in male patients and it has the particularity to be androgen dependent. The aim of the current study was to provide an overview about the interest of testosterone dosage during the management of PCa regardless of the stage of the disease. PATIENTS ET METHODS: A systematic review of the literature was done from the PubMed database by searching the following key words alone or in combination: prostate cancer; testosterone; risk; aggressiveness; hormonotherapy; active surveillance; prognosis; androgen; cardiovascular risk; biochemical recurrence. RESULTS The level of plasmatic testosterone depends on the moment of the day with a peak between the end of the night and in the morning. We can test either the whole testosterone level, the free testosterone level or the bioavailable testosterone. The bioavailable testosterone is more representative of the presence of androgen in tissues but a specialized laboratory is mandatory. The testosterone plasmatic rate is potentially useful during several steps of the PCa management: in localized prostate cancer cases, men with low testosterone levels are more likely to have an aggressive disease and are therefore not good candidates for active surveillance. An extensive radical prostatectomy should be considered in case of young men since these patients are more likely to recur subsequently; in advanced prostate cancer cases, a testosterone level has to be less or equal to 0.2 ng/mL to guarantee an appropriate castration when a patient is undergoing an androgen deprivation treatment. A dissociation between the trend of PSA and testosterone levels can be the starting point of the castration-resistant period of the disease. CONCLUSION The testosterone level can bring useful information regarding the profile of PCa and its ability to evolve during the whole natural history of the disease.
Collapse
Affiliation(s)
- J Lasselin
- Service d'urologie, l'hôpital Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, groupe de recherche GRC 5 oncotype, institut universitaire de cancérologie de l'UPMC, faculté de médecine Pierre-et-Marie-Curie, université Paris VI, bâtiment Gaston-Cordier, 83, boulevard de l'Hôpital, 75013 Paris, France
| | | | | | | | | | | | | | | |
Collapse
|
10
|
García-Cruz E, Carrión Puig A, García-Larrosa A, Sallent A, Castañeda-Argáiz R, Piqueras M, Ribal MJ, Leibar-Tamayo A, Romero-Otero J, Alcaraz A. Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy. Scand J Urol 2012. [DOI: 10.3109/00365599.2012.747562] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
11
|
Risques prostatiques de la testostérone : nouveau retour du balancier? Basic Clin Androl 2012. [DOI: 10.1007/s12610-012-0171-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Résumé
Depuis les années 1940, la testostérone (T) est réputée dangereuse pour la prostate, bien que sans preuve solide. Les études longitudinales ne montrent pas de corrélation entre taux de T et incidence des cancers de la prostate (CaP), dont les formes graves sont au contraire associées à des taux faibles de cette hormone. Les essais cliniques randomisés contre placebo de traitement par la T n’ont pas montré d’augmentation de l’incidence du CaP dans les groupes T. Ces données rassurantes ont conduit certains à prescrire des traitements de substitution androgénique à des hommes porteurs de néoplasies intra-épithéliales prostatiques, ou précédemment traités pour un CaP de bon pronostic, ou sous surveillance active pour un tel cancer non traité, sans qu’apparaisse un risque élevé de progression ou de récidive du CaP sous ce traitement. Il ne fait pourtant aucun doute que la prostate normale et son cancer, au moins dans ses formes évoluées, sont faits de tissus androgénodépendants. Ces apparentes contradictions pourraient s’expliquer, outre par la possibilité d’une très faible diffusion de la T circulante dans le tissu prostatique, par l’hypothèse d’une saturation des récepteurs androgéniques prostatiques dès des niveaux très bas de T circulante, proches des taux de castration, expliquant qu’une augmentation de la T au-delà de ce niveau ne puisse pas stimuler le tissu prostatique. Quelques publications récentes d’évolution de CaP sous traitement androgénique, persistant parfois à l’arrêt de ce traitement, montrent qu’on ne peut pas généraliser les résultats très favorables des études précédentes. Des données objectives suggèrent aussi que le niveau de saturation du récepteur androgénique prostatique pourrait être en réalité proche de la limite inférieure des taux physiologiques de T. Il faut donc rester prudent avant d’élargir les indications du traitement par la T chez les hommes avec antécédent de CaP. Seules des études randomisées à grande échelle, en double insu contre placebo, permettront de se faire une idée exacte des risques auxquels expose ce traitement.
Collapse
|
12
|
Low serum testosterone levels are predictive of prostate cancer. World J Urol 2011; 31:247-52. [PMID: 22068548 DOI: 10.1007/s00345-011-0793-x] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2011] [Accepted: 10/28/2011] [Indexed: 01/14/2023] Open
Abstract
PURPOSE Although hormones play fundamental roles in prostate growth, their clinical significance is not completely clear. Aims of present study were to assess whether testosterone and serum sex hormone levels are predictors of benign prostatic hyperplasia (BPH) or prostate cancer (PC) and to verify whether prostate cancer is associated with low testosterone levels, and to test association between testosterone levels and known prognostic factors in prostate cancer. METHODS In 206 consecutive patients with benign prostatic hyperplasia or prostate cancer testosterone, follicle-stimulating hormone, luteinizing hormone and prolactin levels were tested and correlated with disease. In patients with prostate cancer, hormone levels were also correlated with known prognostic factors. Predictive value was assessed for age, prostate-specific antigen (PSA), PSA ratio, PSA density, prostate volume and serum sex hormone levels using multiple logistic regression analysis and receiver operating characteristic curves. RESULTS Considering sex hormones, only testosterone levels were significantly lower in patients with prostate cancer than those with BPH; testosterone levels appear to be independent predictor of prostate cancer, enhancing predictive accuracy for BPH and PC. Testosterone levels do not seem to be associated with known clinical prognostic factors. CONCLUSIONS This study supports experimental findings that testosterone levels are predictor of prostate cancer and that prostate cancer is frequently associated with low testosterone levels. In the diagnostic work-up for prostate cancer, adding testosterone determination to PSA test may improve predictive accuracy.
Collapse
|